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Abstract
Background: Few studies have analyzed predictors of length of stay (LOS) in patients admitted due to acute
bipolar manic episodes. The purpose of the present study was to estimate LOS and to determine the potential
sociodemographic and clinical risk factors associated with a longer hospitalization. Such information could be
useful to identify those patients at high risk for long LOS and to allocate them to special treatments, with the aim
of optimizing their hospital management.
Methods: This was a cross-sectional study recruiting adult patients with a diagnosis of bipolar disorder (Diagnostic
and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) criteria) who had been hospitalized
due to an acute manic episode with a Young Mania Rating Scale total score greater than 20. Bivariate correlational
and multiple linear regression analyses were performed to identify independent predictors of LOS.
Results: A total of 235 patients from 44 centers were included in the study. The only factors that were significantly
associated to LOS in the regression model were the number of previous episodes and the Montgomery-Åsberg
Depression Rating Scale (MADRS) total score at admission (P < 0.05).
Conclusions: Patients with a high number of previous episodes and those with depressive symptoms during
mania are more likely to stay longer in hospital. Patients with severe depressive symptoms may have a more
severe or treatment-resistant course of the acute bipolar manic episode.
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Background
According to epidemiological studies, the estimated life-
time prevalence of bipolar disorder in Europe is approxi-
mately 1% [1,2]. However, thep r e v a l e n c ea n di n c i d e n c e
rates are probably underestimated. A Spanish study
found that only 30% of patients received a bipolar disor-
der diagnosis on first evaluation [3] and misdiagnosis is
especially frequent in young people [4]. Bipolar disorder
is often associated with other coexisting morbidities, the
most common being anxiety and substance use disorders
[5-7], which are related to an increased risk of suicidal
ideation [8] and of mood switches from depression to
mania [9,10].
In the 15 to 44 age group, bipolar disorder is among
the leading causes of disability in the developed world
[11], which partially explains the important economic
burden of the disease. Additionally, bipolar disorder
patients use healthcare services more than patients with
other mental disorders [12]. Hospital admission is gener-
ally required in acute manic episodes, which are difficult
to treat in outpatient settings due to insufficient adher-
ence to treatment, and also in episodes with severe
depressive symptoms and increased suicide risk [13]. The
costs associated with the hospitalization of patients dur-
ing acute episodes represent the largest share of the
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intervention that could reduce the need for hospitaliza-
tion would have a significant impact on the costs asso-
ciated with the disease [15].
Length of stay (LOS) has been reported to be an impor-
tant factor for determining the relative cost effectiveness
of treatments for bipolar disorder [16]. Therefore, mana-
ging the cost of healthcare related to this illness requires
better information regarding the factors contributing to
LOS. Several studies have identified different sociodemo-
graphic characteristics as predictors for longer LOS: age,
history of commitment, recent employment history,
accommodations problems, and living in areas lacking
community services [17-22]. Tulloch et al. recently pub-
lished a systematic review on the length of stay of general
psychiatric inpatients in the USA. Psychosis, female gen-
der and larger hospital size were associated with longer
LOS [23]. In bipolar patients, mixed episodes [13] and
the Young Mania Rating Scale (YMRS) insight and lan-
guage/thought disorder subscores [24] are some of the
factors that have also been associated with longer LOS.
Few studies have analyzed the relative contribution of
diagnosis, demographic and social data and severity of ill-
ness in predicting LOS in patients hospitalized due to
bipolar mania. Such information could be useful for iden-
tifying those patients at high risk for long LOS and for
allocating them to special treatments, with the aim of
optimizing their hospital management and achieving bet-
ter clinical outcomes.
The aim of this study was to estimate LOS in patients
admitted due to acute bipolar manic episodes and to
determine the potential demographic and clinical risk
factors associated with a longer LOS in this group of
patients.
Methods
Study design
A multicenter, cross-sectional study was carried out in
hospitalized patients with acute manic episodes. The
study was conducted in 44 centers throughout Spain
from November 2007 to July 2008. Mental health ser-
vices are primary funded from taxes in Spain, and LOS
is free of charge [25].
All patients provided written informed consent to par-
ticipate in the study. The study was conducted in accor-
dance with the ethical principles of the Declaration of
Helsinki and was reviewed and approved by the Ethics
Committee of the Hospital Clinico San Carlos (Madrid,
Spain).
Patients
The specific inclusion criteria were: adults aged 18 to 65
years; a bipolar disorder diagnosis based on the Diagnos-
tic and Statistical Manual of Mental Disorders,4 t h
edition, text revision (DSM-IV-TR); hospitalization
admission due to an acute manic episode (as defined by
the DSM-IV-TR); total YMRS [26] score > 20; and
patient ability to understand and comply with the
requirements of the study. Exclusion criteria were: men-
tal retardation, manic episode associated to drug use
according to the investigator criterion, participation in a
clinical trial with drugs within the 30 days prior to the
inclusion in the study, and any clinical contraindication
considered by the investigator.
Assessments
Sociodemographic and illness history data were collected
from medical records and clinical interviews. Psycho-
metric evaluations were made within the first 24 h fol-
lowing the hospital admission and included the following
scales to assess the intensity of mania and coexisting
anxiety and depression symptoms: YMRS [26], the
Hamilton Anxiety Rating Scale (HARS) [27], the Hamil-
ton Depression Rating Scale 5 items (HDRS5) [28], the
Montgomery-Åsberg Depression Rating Scale (MADRS)
[27], and the modified Clinical Global Impression - Bipo-
lar Disorder severity of illness scale (CGI-BP) [29]. The
CGI-BP consists of three subscales providing an overall
illness score and scores for manic (CGI-BP-M) and
depressive symptoms (CGI-BP-D). Additionally, the gen-
eral items of the Scale of Unawareness of Mental Disor-
ders (SUMD) [30] were used to assess insight.
Statistical analysis
LOS was defined as the total number of days a patient
spent as full-time inpatient. Since LOS distribution was
positively skewed (Shapiro-Wilk W test P < 0.01), no
parametric tests (Spearman’s correlation, Mann Whitney
U test, Kruskal-Wallis test) were used to evaluate the
unadjusted association between independent variables
and LOS. The following variables were considered in the
univariate analyses: sociodemographic variables (sex, age,
cohabitation, and educational level), clinical factors
(polarity of the onset episode, number and polarity of
previous episodes, number of previous hospitalizations,
presence of suicidal ideation, number of suicide attempts
and family history of psychiatric disorders) and psycho-
metric evaluations.
Only those variables with P ≤ 0.2 in the univariate ana-
lysis were included in a Cox regression analysis with
backward elimination method to identify whether they
were independent predictorso fL O S .T h es e l e c t i o no f
survival analysis instead of linear models is based on pre-
vious studies that have used this time-to-event analysis to
predict LOS in a variety of disease conditions. The corre-
lation matrix for the independent variables was examined
to detect potential multicolinearity problems in model
building and to select the final candidate predictors to be
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tionally, a multiple regression analysis was performed to
identify independent predictors of mania severity in this
group of patients. Data analysis was performed using
SAS V.8.02 (SAS, Cary, NC, USA).
Results
We recruited 235 patients, 102 male and 133 female. The
mean (SD) age was 43.0 (12) years (range, 18 to 65 years).
Most patients (n = 152; 64.7%) had a manic episode as the
first recognized bipolar disorder episode. A total of 185
patients (78.7%) presented past depressive episodes, 193
(82.1%) manic episodes, 65 (27.7%) hypomanic episodes
and only 51 (21.7%) mixed episodes. The mean numbers
of lifetime prior manic and depressive episodes of bipolar
disorder were 3.9 (4.5) and 2.4 (3.0), respectively. Of the
235 patients, the index admission was the first for 47
patients (20%). Table 1 summarizes the main sociodemo-
graphic and clinical characteristics of the sample.
The final sample for the LOS analysis comprised 214
admissions (21 patients were excluded because length of
hospitalization was not available). The median LOS in
this group of patients was 18 days (range, 1 to 73 days).
There were no differences in LOS according to any of the
sociodemographic variables considered (sex, age and
cohabitation). The number of previous episodes was the
only psychiatric history variable that seemed to be corre-
lated with LOS in the univariate analysis (P ≤ 0.2). All the
psychometric variables had a P ≤ 0.2 in the univariate
analyses, however some of them were not included in the
final model due to their high correlation (r > 0.5) with
other variables selected based on clinical criteria. Thus,
while YMRS score was highly correlated with CGI-BP-M
score, MADRS score was highly correlated with HDRS,
HARS and CGI-BP-D scores (Table 2).
Five independent variables were included in the Cox
regression model based on their likely association to LOS
according to univariate analyses results: the number of
previous episodes (both depressive and maniac), YMRS,
SUMD, MADRS and CGI-BP scores. These variables
were positively correlated to LOS as it is shown in Table
3. The only factors that were significantly associated with
L O Si nt h eC o xr e g r e s s i o nm o d e lw e r et h en u m b e ro f
previous episodes and MADRS score within the first 24 h
following the hospital admission (P =0 . 0 0 1a n dP =
0.030, respectively) (Table 4). Both factors decreased the
probability of discharge (that is, a longer length of stay)
(HR < 1.0).
Correlation between MADRS individual item scores
and LOS were calculated in order to evaluate which
items might contribute more to predict LOS. The score
of two items (concentration difficulties and inability to
feel) were significantly positively correlated with LOS
(r = 0.273 and r = 0.241, respectively; P < 0.05).
Severity of mania assessed with the YMRS scale was
not a significant predictor of LOS according to the
results of the Cox regression analysis. The effect of
YMRS score on LOS might be obscured by other factors
included in the analysis that were also related to mania
severity. In order to clarify this point, a multivariate lin-
ear regression analysis was performed to identify inde-
pendent predictors of mania severity in this group of
patients. As in the Cox regression model, a preliminary
univariate analysis including the 235 patients allowed to
select those sociodemographic, clinical and psychometric
variables to be included as likely covariates of the final
model. To rule out circularity effects, potential direct
correlates of YMRS, such as CGI-BP-M, were not used.
The results of the multivariate linear regression analysis
indicated that YMRS was significantly explained by
SUMD and MADRS scores (P <0 . 0 1 ) .W h i l eS U M D
score explained approximately 15% (R
2 = 0.149) of the
variation, MADRS score explained only the 4.8% (R
2 =
0.048). Two items of the MADRS, reduced sleep and
concentration difficulties, were significantly positively
correlated with YMRS score (r = 0.316 and r = 0.280,
respectively; P < 0.05).
Discussion
The main finding of this study was that patients with
higher score on the MADRS scale and/or a larger num-
ber of previous episodes were more likely to remain
Table 1 Demographic and clinical characteristics of the
sample
Variable Value
Age in years, mean (SD) 43.0 (12.0)
Female gender, N (%) 133 (56.9)
Living alone, N (%) 38 (16.4)
Primary/secondary education only, N (%) 187 (79.5)
Polarity of the first episode, N (%):
Depressive 74 (31.5)
Manic 152 (64.7)
Hypomanic 5 (2.1)
Mixed 4 (1.7)
Suicide attempts, N (%) 59 (25.1)
Family history of psychiatric disorders, N (%) 107 (45.5)
YMRS score, mean (SD) 33.3 (6.9)
MADRS score, mean (SD) 14.8 (7.0)
HARS score, mean (SD) 14.3 (7.1)
CGI-BP overall score, mean (SD) 4.4 (1.4)
CGI-BP mania score, mean (SD) 5.2 (0.8)
CGI-BP depression score, mean (SD) 2.0 (1.1)
SUMD overall score, mean (SD) 9.5 (3.5)
CGI-BP = Clinical Global Impression - Bipolar Disorder Scale; HARS = Hamilton
Anxiety Rating Scale; MADRS = Montgomery-Åsberg Depression Rating Scale;
SUMD = Scale to Assess Unawareness of Mental Disorder; YMRS = Young
Mania Rating Scale.
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patients with severe depressive symptoms might also
have a more severe or treatment-resistant course of the
acute bipolar manic episode. This result highlights the
importance of evaluating depressive symptoms in hospi-
talized patients with acute manic episodes.
Our results are consistent with evidence that hospitali-
zations for mixed episodes are longer than hospitaliza-
tions for depressive and manic episodes [13,31,32]. Ösby
et al. observed that LOS was not different between
manic (29.2 days) or depressive episodes (29.9 days), but
was longer for mixed episodes (42.3 days) [13]. Another
study carried out in Spain also found some differences
in LOS according to the type of episode: 17.5, 18.4 and
21.9 days for manic, depressive and mixed episodes,
respectively [31]. While in these studies a categorical
assessment of the polarity of the episodes was used, in
our study we used a dimensional perspective that
yielded similar results.
These data are clinically significant and should stimu-
late further research in the field of depression monitoring
and treatment during manic episodes. In addition to the
economic impact of prolonged hospitalization in patients
with bipolar disorders, longer LOS could have also a
deleterious effect on the outcome of the patients or
undermine the benefits of treatment.
Patients with more previous episodes may be more
likely to stay longer in the hospital because they may
have higher propensity to switch and fluctuate during
hospitalization than patients with fewer episodes. More-
over, number of previous episodes has been consistently
associated with severity of illness and lack of response
in the current episode, allowing a longer stay in hospital
[33,34].
Nowadays, the majority of patients are treated in out-
patient settings and LOS in general hospital psychiatric
units is measured in days [18]. However, the cost of hos-
pitalization still represents the most significant portion of
the direct costs of bipolar disorder. The mean direct cost
associated with healthcare resource utilization during the
manic episode was of nearly €4,500 per patient in Spain,
55% of this amount corresponding to the cost of hospita-
lization [15]. The costs of mania have been shown to be
quite similar in different European countries [32]. Our
study found patients with depressive symptoms during a
m a n i ce p i s o d ea r em o r el i k e l yt os t a yl o n g e r .M a n a g i n g
the costs associated with bipolar disorder patient care is
critical due to worldwide budget containment measures.
Any drug intervention in the management of mixed epi-
sodes that reduces the severity of both manic and depres-
sive symptoms could have a significant impact on the
costs associated with the disease. In addition, according
to our results, mixed episodes should be reimbursed at
different rates than pure manic or depressive episodes.
Overall, severity of mania measured with the YMRS
scale was not a significant predictor of LOS according
to our results. However, a previous study carried out in
Table 2 Correlation matrix among psychometric variables
YMRS HARS HDRS5 SUMD CGI-BP-D CGI-BP-M CGI-BP MADRS
YMRS 1.000 0.215** 0.043 0.397** -0.114 0.532** 0.250** 0.143**
HARS 1.000 0.646** -0.076 0.486** 0.107 0.155* 0.665**
HDRS5 1.000 -0.209** 0.677** -0.015 0.091 0.712**
SUMD 1.000 -0.310** 0.294** 0.200** -0.162
CGI-BP-D 1.000 -0.033 0.206** 0.680**
CGI-BP-M - 1.000 0.403** 0.055
CGI-BP 1.000 0.292**
MADRS 1.000
Significant correlation coefficients > 0.5 are shown in bold.
*P < 0.05, **P < 0.01.
CGI-BP = Clinical Global Impression - Bipolar Disorder Scale; CGI-BP-D = Clinical Global Impression-Bipolar Disorder Scale Depression; CGI-BP-M = Clinical Global
Impression-Bipolar Disorder Scale Mania HARS = Hamilton Anxiety Rating Scale; HDRS5 = Hamilton Depression Rating Scale 5 items; MADRS = Montgomery-
Åsberg Depression Rating Scale; SUMD = Scale to Assess Unawareness of Mental Disorder; YMRS = Young Mania Rating Scale.
Table 3 Spearman’s correlation coefficients of variables
included in the Cox regression model
Spearman’s correlation P value
Number of previous episodes 0.115 0.093
YMRS score 0.206 0.003
SUMD score 0.114 0.096
CGI-BP score 0.125 0.073
MADRS score 0.185 0.007
CGI-BP = Clinical Global Impression - Bipolar Disorder Scale; MADRS =
Montgomery-Åsberg Depression Rating Scale; SUMD = Scale to Assess
Unawareness of Mental Disorder; YMRS = Young Mania Rating Scale.
Table 4 Independent predictors of LOS in the
multivariate Cox regression model
Predictors Hazard ratio 95% CI P value
Number of previous episodes 0.978 0.959 to 0.997 0.021
MADRS score 0.981 0.962 to 1.000 0.045
MADRS = Montgomery-Åsberg Depression Rating Scale; LOS = length of stay.
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found that only YMRS, insight and language/thought
disorder subscores to predict longer LOS [24]. The
inclusion of the MADRS score in our analysis may
explain our results. The MADRS item ‘inability of feel’,
which was positively correlated with LOS in our study,
has been considered as a core depressive symptom by
some authors [35]. However, since some of the other
MADRS items are susceptible to contamination by a
manic state, such as sleep reduction, appetite reduction,
concentration difficulties and inner tension, it could be
thought that the effect of the MADRS score on LOS
could be explained by the manic symptoms included in
this scale. Nevertheless, the results of the multivariate
linear regression analysis indicated that the MADRS
score only explained 4.8% of the variation in the YMRS
score. Moreover, only two items of the MADRS,
reduced sleep and concentration difficulties were signifi-
cantly and positively correlated to the YMRS score. The
fact that reduced sleep and distractibility correlated with
the YMRS score indicates that these symptoms are not
specific of depression. Some of the MADRS items, such
as those two, may actually be measuring symptoms that
can be ascribed to a manic syndrome, but other items
are unequivocally linked to depression and not mania.
Most definitions of mixed states actually acknowledge
that not all depressive symptoms qualify as ‘core’ symp-
toms of one pole only [36,37].
The SUMD score explained a higher variance of the
YMRS (15%). Lack of insight is a core symptom during
mania, represents one of the treatment targets during
hospitalizations, and is highly associated to treatment
non-adherence [38]. Our findings indicate that the
SUMD scores correlated positively with the YMRS
scores and negatively with the MADRS scores, which is
consistent with the fact that manic patients are more
likely to be unaware of their condition than depressed
patients. However, we did not find a correlation between
SUMD and LOS. These results led us to confirm the
predictive and independent effect of depression symp-
toms on LOS in acute manic episodes.
Limitations
A limitation of this study was the lack of assessment of
additional factors related to length of stay in patients with
bipolar disorder, such as hospital profile, the availability of
community health centers, mean LOS of previous hospita-
lizations or pharmacological treatment received [23,39]. In
addition, comorbidity and drug use were not assessed,
which may be relevant factors affecting LOS [22,40].
Conclusions
Our study indicates that patients with a large number of
previous episodes and those with depressive symptoms
during mania are more likely to stay longer in hospital and
may need more intensive treatment than purely manic
patients with few previous episodes. This underscores the
importance of defining a better clinical approach to acute
manic episodes with depressive symptoms with the ulti-
mate goal of achieving a better clinical outcome.
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